6. Attenuation of Non-Alcoholic Hepatic Steatohepatitis (NASH) as a Possible Mechanism of Anti-Atherosclerotic Action of FFAR4. This evidence concerns the gene FFAR4 and metabolic dysfunction-associated steatohepatitis.